Last $62.65 USD
Change Today -2.44 / -3.74%
Volume 3.9M
ISIS On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 3:21 PM 12/22/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

2855 Gazelle Court

Carlsbad, CA 92010

United States

Phone: 760-931-9200

Fax:

Isis Pharmaceuticals, Inc. is engaged in the discovery and development of antisense drugs using novel drug discovery platform. Drug Discovery and Development Development Projects The company’s main product, KYNAMRO (mipomersen sodium) injection, is on the market in the United States for patients with homozygous familial hypercholesterolemia (HoFH). In 2013, the U.S. Food and Drug Administration (FDA) approved the marketing application for KYNAMRO for patients with HoFH. Genzyme, a Sanofi Company, has also obtained marketing approval in other countries, including Mexico, Argentina and South Korea, and is pursuing marketing approval in multiple additional markets. Severe and Rare Disease Franchise Alicaforsen — Under license to Atlantic Pharmaceuticals Limited, alicaforsen is an antisense drug that targets intercellular adhesion molecule 1, or ICAM-1. ISIS-TTRRx: ISIS-TTRRx is an antisense drug that the company designed to treat transthyretin amyloidosis, or TTR amyloidosis, a severe and rare genetic disease in which the patient inherits a mutant gene that produces a misfolded form of TTR, which progressively accumulates in tissues. In patients with TTR amyloidosis, both the mutant and normal forms of TTR could build up as fibrils in tissues, including heart, peripheral nerves, and the gastrointestinal tract. ISIS-SMNRx: ISIS-SMNRx is an antisense drug that the company designed to treat spinal muscular atrophy, or SMA, a severe motor-neuron disease that is the major genetic cause of infant mortality. The company designed ISIS-SMNRx to treat various types of childhood SMA by altering the splicing of a closely related gene, SMN2, which leads to the increased production of fully functional SMN protein. ISIS-APOCIIIRx: ISIS-APOCIIIRx is an antisense drug that the company designed to reduce apolipoprotein C-III, or apoC-III, protein production and lower triglycerides. It is evaluating ISIS-APOCIIIRx for use in patients with severely elevated triglycerides of approximately 880 mg/dL. ATL1103: ATL1103 is an antisense drug that targets the growth hormone receptor, or GHr, a receptor that, when inhibited, reduces the level of circulating insulin-like growth factor-1, or IGF-1, produced in the liver. IGF-1 is a hormone that contributes to various diseases, including acromegaly, an abnormal growth disorder of organs, face, hands, and feet. IGF-1 also contributes to diabetic retinopathy, a common disease of the eye and a leading cause of blindness, diabetic nephropathy of the kidney and certain forms of cancer. In preclinical studies, ATL1103 demonstrated significant reductions in IGF-1 levels in the blood and inhibition of neovascularization, or new blood vessels, in the eye in a mouse retinopathy model. Antisense Therapeutics Limited is in the process of developing ATL1103. Antisense Therapeutics Limited has completed a Phase 1 study in healthy volunteers demonstrating that ATL1103 was safe and well tolerated. It is evaluating ATL1103 in a Phase 2 study in patients with acromegaly. ISIS-GCCRRx: ISIS-GCCRRx is an antisense drug that targets the glucocorticoid receptor, or GCCR. Glucocorticoid hormones affect various processes throughout the body, and excessive levels of glucocorticoid hormones could have a detrimental effect on majority of the tissues and organs in the body. ISIS-PKKRx: ISIS-PKKRx is an antisense drug designed to prevent hereditary angioedema, or HAE, attacks. ISIS-PKKRx inhibits the production of prekallikren, or PKK, a protein produced in the liver that plays an important role in the activation of inflammatory mediators associated with acute attacks of HAE. HAE is a rare genetic disease that is characterized by rapid and painful attacks of inflammation in the hands, feet, limbs, face, abdomen, larynx, and trachea. ISIS-DMPKRx: ISIS-DMPKRx is an antisense drug that the company designed to correct the underlying genetic defect that causes Myotonic Dystrophy Type 1, or DM1. Cardiovascular Franchise The company is in the process of developing a drug that lowers apoC-III and triglycerides, which are both independent risk factors for cardiovascular disease. ISIS-APOCIIIRx —

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ISIS:US $62.71 USD -2.38

ISIS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ACADIA Pharmaceuticals Inc $32.31 USD -0.67
Acorda Therapeutics Inc $39.78 USD -0.28
Avanir Pharmaceuticals Inc $16.93 USD +0.08
Depomed Inc $16.07 USD -0.17
Regulus Therapeutics Inc $15.79 USD -0.99
View Industry Companies
 

Industry Analysis

ISIS

Industry Average

Valuation ISIS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 44.7x
Price/Book 22.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 39.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ISIS PHARMACEUTICALS INC, please visit www.isispharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.